Health score, competitive moat, risk signals, and key metrics at a glance.
Competitive analysis based on 61 quarters of fundamental data
Operating margins are expanding at ~107.7%, suggesting durable pricing power and cost discipline.
ROE is positive at ~10.5% on average, adequate but below the threshold typically associated with wide moats.
Data-driven red flags and warnings across 61 quarters
Margins are stable or improving at ~122.5% — no sign of cost or pricing stress.
FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.
D/E ratio is 0.7 — conservative capital structure with low financial risk.
Revenue declined in 7 of the last 7 quarters — persistent contraction signals a fundamental problem.
FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.
Shares decreased 3.8% — net buybacks are reducing shares outstanding and boosting per-share value.
as of September 2025
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
5 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
